Emerson Electric Co. (EMR) emerges as an undervalued dividend aristocrat following significant transactions reported by various institutional investors and financial groups. The coverage includes Baird Financial Group and AQR Capital Management selling their shares, while Chapman Financial Group, Brown Advisory, BLI Banque de Luxembourg Investments, Ameriprise Financial, Deprince Race & Zollo, Cary Street Partners, and Bayesian Capital Management LP made investments. Also, CoreCap advisors and Cetera Investment Advisors sold EMR shares. Emerson Electric had strong Q2 2025 earnings results and raised guidance for the future. Investment firms like Wells Fargo, Citigroup, and Barclays raised price targets for the company. Second quarter earnings beat estimates and had notable impact on the stock price. A noticeable mention is the AspenTech acquisition. The company declared quarterly dividend and provided upbeat earnings guidance for 2025. Negative points include lower price targets set by Robert W. Baird and being tagged as a risky investment. There were also reports of EMR's stock underperforming compared to its earnings growth. Despite this, it's suggested to buy EMR on the dip.
Emerson Electric EMR News Analytics from Thu, 23 Jan 2025 08:00:00 GMT to Sat, 10 May 2025 22:55:29 GMT -
Rating 7
- Innovation 3
- Information 6
- Rumor -3
